Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sunitinib maleate.

× No keyword cloud information.

27 in total

1. Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions.

Authors: Brian P Rubin
Journal: Skeletal Radiol Date: 2007-04 Impact factor: 2.199

2. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.

Authors: Romain Coriat; Stanislas Ropert; Olivier Mir; Bertrand Billemont; Stanislas Chaussade; Pierre-Philippe Massault; Benoit Blanchet; Olivier Vignaux; François Goldwasser
Journal: Invest New Drugs Date: 2010-06-05 Impact factor: 3.850

3. Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.

Authors: Anabel Sorolla; Andrée Yeramian; Joan Valls; Xavier Dolcet; Laura Bergadà; Antoni Llombart-Cussac; Rosa Maria Martí; Xavier Matias-Guiu
Journal: Mol Oncol Date: 2012-07-07 Impact factor: 6.603

Review 4. Succinate dehydrogenase-deficient gastrointestinal stromal tumors.

Authors: Ya-Mei Wang; Meng-Li Gu; Feng Ji
Journal: World J Gastroenterol Date: 2015-02-28 Impact factor: 5.742

5. N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.

Authors: Aleem Gangjee; Sonali Kurup; Michael A Ihnat; Jessica E Thorpe; Bryan Disch
Journal: Bioorg Med Chem Date: 2011-12-08 Impact factor: 3.641

Review 6. Targeting the RAS pathway in melanoma.

Authors: Zhenyu Ji; Keith T Flaherty; Hensin Tsao
Journal: Trends Mol Med Date: 2011-09-30 Impact factor: 11.951

7. The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.

Authors: Mohamed M Mohyeldin; Mohamed R Akl; Abu Bakar Siddique; Hossam M Hassan; Khalid A El Sayed
Journal: Biochem Pharmacol Date: 2016-12-08 Impact factor: 5.858

Review 8. Present and future evolution of advanced breast cancer therapy.

Authors: Ricardo H Alvarez
Journal: Breast Cancer Res Date: 2010-10-22 Impact factor: 6.466

9. Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.

Authors: Matthew D Hall; Noeris K Salam; Jennifer L Hellawell; Henry M Fales; Caroline B Kensler; Joseph A Ludwig; Gergely Szakács; David E Hibbs; Michael M Gottesman
Journal: J Med Chem Date: 2009-05-28 Impact factor: 7.446

10. Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.

Authors: M Preusser; M Hutterer; M Sohm; O Koperek; K Elandt; K Dieckmann; D Prayer; C Marosi
Journal: J Neurooncol Date: 2009-10-10 Impact factor: 4.130